Lyon, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced the participation of the Poxel team in several scientific conferences to come in May 2022.
65and Japan Diabetes Society JDS Annual Meeting – Kobe, Japan
Date: May 12-14, 2022
Pascale Fouqueray, Executive Vice President, Clinical Development and Regulatory Affairs at Poxel will give an online presentation on Imeglimin titled: “A new approach to anti-diabetic drug development: from seed screening to pipeline development”.
European Kidney Association – Paris, France
Date: May 25-28, 2022
Pascale Gluais Dagorn, Pharmacology Director at Poxel, will give an online presentation on PXL770 in polycystic kidney disease entitled: “Preclinical efficacy of direct activation of AMPK with a new small molecule – PXL770 – for the treatment of autosomal dominant polycystic kidney disease“.
5and NASH World Congress – London, UK
Date: May 26-27, 2022
Sébastien Bolze, Executive Vice-President and Chief Operating Officer of Poxel will be present in person and will give a presentation on PXL065 in the NASH titled: “Preclinical and early clinical characterization of PXL065 – Stabilized Deuterium (R) -Pioglitazone – a potential new oral therapy for NASH”.
About Poxel AG
Poxel is a clinical-stage biopharmaceutical company development innovative treatments for serious chronic diseases with metabolic pathophysiologyincluding non-alcoholic steatohepatitis (NASH) and rare diseases. Poxel has clinical and early-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (stabilized with deuterium R-pioglitazone) is undergoing a simplified phase 2 trial (DESTINY-1). PXL770a first-in-class direct AMPK activator, successfully completed a phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the Company intends to initiate Phase 2a proof-of-concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s Lead Product Targeting Mitochondrial Dysfunction, Approved and Launched for the Treatment of Type 2 Diabetes in Japan. Poxel expects to receive royalties and sales-based payments from Sumitomo Pharma. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate additional growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, visit: www.poxelpharma.com